Literature DB >> 12687540

Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis.

Soon-Min Tan1, Dong Xu, Viktor Roschke, James W Perry, Daniel G Arkfeld, Glenn R Ehresmann, Thi-Sau Migone, David M Hilbert, William Stohl.   

Abstract

OBJECTIVE: To determine whether synovial fluid (SF) levels and cell-surface expression of B lymphocyte stimulator (BLyS) protein and SF levels of APRIL are elevated in patients with inflammatory arthritis (IA).
METHODS: Same-day blood and SF samples from 89 patients with 103 knee effusions (81 knees with IA and 22 with noninflammatory arthritis [NIA]) were evaluated for BLyS protein and APRIL levels by enzyme-linked immunosorbent assay. Blood and SF mononuclear cells were double-stained for surface BLyS protein and surface CD14 (monocyte marker) and were analyzed by flow cytometry. Complete blood cell counts and SF nucleated cell counts were performed by the clinical hematology laboratory.
RESULTS: BLyS protein levels were higher in SF than in corresponding serum samples from both IA and NIA patients. SF BLyS protein levels, but not surface expression of BLyS protein, were disproportionately elevated in IA patients. APRIL levels were higher in SF than in corresponding serum samples from most IA patients but not NIA patients. SF BLyS protein and APRIL levels correlated with each other, and each correlated with SF monocyte, lymphocyte, neutrophil, and total nucleated cell counts. Although SF and serum BLyS protein levels correlated with each other, SF and serum APRIL levels did not, suggesting that SF BLyS protein levels are more dependent upon systemic factors than are SF APRIL levels. Moreover, in 8 patients who underwent sequential arthrocenteses, changes in SF BLyS protein levels did not immutably parallel changes in SF APRIL levels, indicating their differential regulation.
CONCLUSION: BLyS protein and APRIL are locally produced in inflamed joints. Their respective SF levels are differentially regulated, suggesting that they serve different functions. Together, their local production may foster survival and/or expansion of B cells that produce pathogenic autoantibodies and/or promote local T cell activation and consequent joint destruction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12687540     DOI: 10.1002/art.10860

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  50 in total

Review 1.  B cells: new ways to inhibit their function in rheumatoid arthritis.

Authors:  Robert H Carter
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

2.  Surface APRIL Is Elevated on Myeloid Cells and Is Associated with Disease Activity in Patients with Rheumatoid Arthritis.

Authors:  Abby Jones Weldon; Ioana Moldovan; Marven G Cabling; Elvin A Hernandez; Sheri Hsu; Jennifer Gonzalez; Andrea Parra; Abigail Benitez; Nasim Daoud; Keith Colburn; Kimberly J Payne
Journal:  J Rheumatol       Date:  2015-03-01       Impact factor: 4.666

3.  A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys.

Authors:  Yulia Vugmeyster; Dhaya Seshasayee; Wesley Chang; Anahid Storn; Kathy Howell; Susan Sa; Tenea Nelson; Flavius Martin; Iqbal Grewal; Ellen Gilkerson; Ben Wu; Jeff Thompson; Barbara N Ehrenfels; Song Ren; An Song; Thomas R Gelzleichter; Dimitry M Danilenko
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

4.  Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies.

Authors:  Stephen A Mihalcik; Renee C Tschumper; Diane F Jelinek
Journal:  Cell Cycle       Date:  2010-12-15       Impact factor: 4.534

Review 5.  B-cell inhibitors as therapy for rheumatoid arthritis: an update.

Authors:  Jennifer Kwan-Morley; Daniel Albert
Journal:  Curr Rheumatol Rep       Date:  2007-10       Impact factor: 4.592

6.  Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.

Authors:  Alain Munafo; Anthony Priestley; Ivan Nestorov; Jennifer Visich; Mark Rogge
Journal:  Eur J Clin Pharmacol       Date:  2007-05-01       Impact factor: 2.953

7.  Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response.

Authors:  Magda Nakou; Georgios Katsikas; Prodromos Sidiropoulos; George Bertsias; Eva Papadimitraki; Amalia Raptopoulou; Helen Koutala; Helen A Papadaki; Herakles Kritikos; Dimitrios T Boumpas
Journal:  Arthritis Res Ther       Date:  2009-08-28       Impact factor: 5.156

8.  Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort.

Authors:  Jacques-Eric Gottenberg; Corinne Miceli-Richard; Béatrice Ducot; Philippe Goupille; Bernard Combe; Xavier Mariette
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

9.  Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs.

Authors:  Manil Kukar; Olga Petryna; Petros Efthimiou
Journal:  Biologics       Date:  2009-10-12

Review 10.  Roles of B cells in rheumatoid arthritis.

Authors:  Gregg J Silverman; Dennis A Carson
Journal:  Arthritis Res Ther       Date:  2003-12-02       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.